PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Revenue Per Share for the year ending December 31, 2023: USD 0.00

PainReform Ltd. Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • PainReform Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 0.08, a 0.00% change year over year.
  • PainReform Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
  • PainReform Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
  • PainReform Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NasdaqCM: PRFX

PainReform Ltd.

CEO Dr. Ehud Geller Ph.D.
IPO Date Sept. 1, 2020
Location Israel
Headquarters 65 Yigal Alon Street
Employees 7
Sector Health Care
Industries
Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Similar companies

RGC

Regencell Bioscience Holdings Limited

USD 4.86

-4.71%

FLGC

Flora Growth Corp.

USD 0.94

1.68%

PROC

Procaps Group S.A.

USD 1.76

7.98%

StockViz Staff

January 15, 2025

Any question? Send us an email